Kyverna Therapeutics, Inc. · NASDAQ:KYTX
Kyverna Therapeutics — Corporate Update (September 2026)
29 slides from Kyverna Therapeutics's corporate update, Sep 24, 2026
Slide 1: Positive Longer-Term Durability and Safety Data of Miv-cel in SPS and gMG
Positive Longer-Term Durability and Safety Data of Miv-cel in SPS and gMG September 24, 2026 ©2026 Kyverna Therapeutics, Inc.
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management’s beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. (“Kyverna”, “we”, “our,” or the “Company”). All statements other than
Slide 3: Today's Agenda
Today’s Agenda Speakers Miv-cel – Setting a New Benchmark for Autoimmune CAR T Stiff Person Syndrome (SPS) – 1-Year Topline Data Warner Biddle Generalized Myasthenia Gravis (gMG) – Chief Executive Officer Phase 2 Longer-term Topline Follow-up Data Transforming the Treatment Paradigm in Neurologic Au
Slide 4: Single Dose Miv-cel Continues to Establish a New Clinical Response Benchmark for Autoimmune CAR T
Single Dose Miv-cel Continues to Establish a New Clinical Response Benchmark for Autoimmune CAR T Durable results for at least 1 year in both SPS and gMG with nearly all patients remaining off chronic immunotherapies Consistent, well-tolerated safety profile maintained in 1-year follow-up with no hi
Slide 5: Miv-cel's Differentiated CAR Construct Reinforces Potential First-in-Class and Best-in-Class Profile
Miv-cel's Differentiated CAR Construct Reinforces Potential First-in-Class and Best-in-Class Profile in Autoimmune Mivocabtagene Autoleucel (miv-cel)1,2 • Deep depletion of peripheral and tissue- Only Fully Human Autologous CD19 resident B cells to support broad immune CAR T With CD28 Costim reset a
Slide 6: Established, Validated, and Scalable Manufacturing Process
Established, Validated, and Scalable Manufacturing Process Miv-cel is produced using a well-established, and validated manufacturing process similar to those used in commercially available CD19 autologous CAR T-cell therapies Dual-source U.S. manufacturing strategy >98% manufacturing success rate dr
Slide 7: SPS – 12-Month Topline Data from KYSA-8 Registrational Trial
SPS – 12- Month Topline Data from KYSA-8 Registrational Trial Naji Gehchan, M.D., MSc, MBA – Chief Medical and Development Officer ©2026 Kyverna Therapeutics, Inc.
Slide 8: KYSA-8 Registrational Trial in SPS – Study Design
KYSA-8 Registrational Trial in SPS – Study Design KYSA-8: Open-label, single-arm, multicenter study N = 26 Primary endpoints: • Age 18 to 75 years Miv-cel • Change from baseline in T25FW at 16 weeks Low-dose Cy/Flu • Safety • Diagnosis of SPS preconditioning One- • Inadequate response + Secondary en
Slide 9: Continued Reversal of Disability with Nearly All Patients Remaining Off Chronic Immunotherapies
Continued Reversal of Disability with Nearly All Patients Remaining Off Chronic Immunotherapies Sustained Through 1 Year Significant T25FW Improvement and Reduced Walking Aid Use • 95% of patients who achieved a clinically meaningful improvement (≥20% reduction from 16-week primary endpoint measurem
Slide 10: Statistically Significant Improvements Continued in All Primary and Secondary Endpoints Through 1 Year
Statistically Significant Improvements Continued in All Primary and Secondary Endpoints Through 1 Year 16-wk timepoint 1-Yr follow-up Primary Endpoint P Value P Value Timed 25-Foot Walk 0.0003 <0.0001 Secondary Endpoints P Value P Value Modified Rankin Scale <0.0001 0.0003 Distribution of Stiffness
Slide 11: Consistent Safety Profile Maintained in 1-Year Follow-Up
Consistent Safety Profile Maintained in 1-Year Follow-Up With No High-Grade CRS or ICANS and No IEC-HS Treatment-Related Adverse N = 26 Events, n (%) • No high-grade CRS or ICANS observed Any grade ≥3 CRS 0 (0) Any grade ≥3 ICANS 0 (0) • No IEC-HS observed Any grade IEC-HS 0 (0) • All Grade 3/4 neut
Slide 12: KYSA-8 Patient Perspectives: Before and After Treatment with Miv-cel
KYSA-8 Patient Perspectives: Before and After Treatment with Miv-cel Case Studies View Video View Video 12
Slide 13: gMG – Longer-Term Data from Phase 2 KYSA-6 Trial
gMG – Longer-Term Data from Phase 2 KYSA-6 Trial Naji Gehchan, M.D., MSc, MBA – Chief Medical and Development Officer ©2026 Kyverna Therapeutics, Inc.
Slide 14: KYSA-6 Phase 2/3 Trial in gMG – Phase 2 Study Design
KYSA-6 Phase 2/3 Trial in gMG – Phase 2 Study Design Phase 2 design: Open-label, single-arm, multicenter study N=7 • Age 18 to 75 years • Diagnosis of gMG, Class IIB-IV per MGFA criteria KYV-101 Primary endpoints • Autoantibodies to AChR, • MG-ADL at 24 weeks 18-month MuSK, or LRP4 Cy/Flu lymphodepl
Slide 15: Robust and Durable Effects Sustained Through At Least 1-Year Across MG-ADL and QMG
Robust and Durable Effects Sustained Through At Least 1-Year Across MG-ADL and QMG MG-ADL Score QMG Score Change from BL Change from BL Baseline Baseline Week 2 Week 24 Week 52 Week 2 Week 24 Week 52 Mean MG-ADL 11.0 –6.9 –8.3 –8.2 Mean QMG 16.9 –8.6 –11.7 –12.8 24-week primary endpoint 24-week prim
Slide 16: Single-dose Miv-cel Continues to Deliver Robust Reductions in MG Outcome Scores and Treatment Burden
Single-dose Miv-cel Continues to Deliver Robust and Clinically Meaningful Reductions in MG Outcome Scores and Treatment Burden Substantially improved clinical outcomes MG-ADL QMG 100% had clinically meaningful response 100% had clinically meaningful response (≥2-point reduction vs baseline) (≥3-poin
Slide 17: Consistent Safety Profile Maintained in Long-term Follow-Up
Consistent Safety Profile Maintained in Long-term Follow-Up With No High-Grade CRS and No ICANS or IEC-HS Treatment-related AEs, n (%) Patients (n=7) • No high-grade CRS and no ICANS observed Any grade ≥3 CRS 0 (0) • No IEC-HS observed Any grade ICANS 0 (0) • All Grade 3/4 treatment-related AEs Any
Slide 18: Opportunity to Achieve Drug-Free, Disease-Free Remission with Single Dose Miv-cel
Opportunity to Achieve Drug-Free, Disease-Free Remission with Single Dose Miv-cel Note: These observations are derived from separate clinical settings; comparisons across trials are not based Approved Investigational on head-to-head studies. FcRn Complement CD19 BCMA mRNA Miv-cel Inhibitor1 Inhibito
Slide 19: Transforming the Treatment Paradigm in Neurologic Autoimmune Diseases
Transforming the Treatment Paradigm in Neurologic Autoimmune Diseases Warner Biddle – Chief Executive Officer ©2026 Kyverna Therapeutics, Inc.
Slide 20: Miv-cel's Value Proposition Supports Commercial Potential Across Multiple Autoimmune Diseases
Miv-cel’s Compelling Value Proposition Supports Strong Commercial Potential Across Multiple Autoimmune Diseases Miv-cel’s Potential - Today’s Treatment Paradigm Drug-Free, Disease-Free Remission Chronic therapy Single dose Inadequate disease management Immune reset Transient benefit Durable benefit
Slide 21: Potential First-Approved Therapy for SPS Represents a Valuable Commercial Neuroimmunology Opportunity
Potential First-Approved Therapy for SPS Represents a Valuable Commercial Neuroimmunology Opportunity Compelling SPS Targeted Launch Strategy Market Dynamics to Maximize Value Creation • Progressive rare disease with no approved therapies • First-in-indication rare disease launch • ~6K U.S. diagnose
Slide 22: Pioneering Differentiated Therapies with Curative Potential to Free People from Life-long Autoimmune Diseases
Pioneering Differentiated Therapies with Curative Potential to Free People from Life-long Autoimmune Diseases and Chronic Therapy Miv-cel BLA Submission Best-in-Class Profile Valuable Commercial Underway for SPS Unique miv-cel construct and Opportunity in SPS Further strengthened by 1-year validated
Slide 23: Q&A
Q&A Warner Biddle Naji Gehchan, M.D., MSc, MBA Greg Martini Chief Executive Officer Chief Medical Chief Financial Officer & Development Officer ©2026 Kyverna Therapeutics, Inc.
Slide 24: Appendix
Appendix
Slide 25: Single Dose Miv-cel Demonstrates Potential to Deliver Drug-Free, Disease-Free Remission in SPS
Single Dose Miv-cel Demonstrates Potential To Deliver Drug-Free, Disease- Free Remission to Patients with SPS, a Disease with No Approved Therapies Sustained improvements through 1 year across all primary and secondary endpoints resulting from deep B-cell depletion and potential for immune reset Con
Slide 26: gMG Data Further Reinforces Potential for Miv-Cel to Provide Broad Immune Reset
gMG Data Further Reinforces Potential for Miv-Cel to Provide Broad Immune Reset with a Single Dose, Increasing Confidence in Phase 3 Trial Robust and durable effects sustained through at least 1 year further differentiate miv-cel from existing chronic therapies Majority of patients maintained MSE as
Slide 27: Primary Endpoint Outcome Assesses Impact of SPS on Walking Ability
Primary Endpoint Outcome Assesses Impact of SPS on Walking Ability Timed 25-Foot Walk (T25FW) 20% improvement • Validated tool to assess walking ability1 considered clinically • Used to evaluate stiffness and loss of mobility in SPS2 meaningful1 • Healthy adults can perform the T25FW in ~4-5 seconds
Slide 28: Secondary Endpoint Outcomes Assess Extent of Disability and SPS-Specific Symptoms
Secondary Endpoint Outcomes Assess Extent of Disability and SPS-Specific Symptoms Modified Rankin Degree of 0 1 2 3 4 5 6 Scale (mRS) disability1 No symptoms Nonsignificant Disability Slight Disability Moderate Disability Moderately Severe Severe Disability Death Disability Hauser Time and degree Am
Slide 29: KYSA-6 Phase 2/3 Trial in gMG – Phase 3 Study Design
KYSA-6 Phase 2/3 Trial in gMG – Phase 3 Study Design ~60-patient, global, open-label, randomized controlled Phase 2/3 trial with crossover design Co-Primary Endpoints (MG-ADL & QMG) Miv-cel Screening, Low-dose Cy/Flu preconditioning + N = ~60 Single infusion of 1×108 CAR T cells Follow Up washout, a
Kyverna Therapeutics — Corporate Update (September 2026) on 6ix